| Short-term improvement in submaximal exercise capacity by optimized therapy with ACE inhibitors and beta blockers in heart failure patients is associated with restoration of peripheral endothelial function. | |
| | |
MedLine Citation:
|
PMID: 16516697 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Improved exercise capacity in chronic heart failure (CHF) has been attributed to restoration of endothelial function. ACE inhibitors as well as beta blockers have previously been shown to enhance endothelial function and exercise capacity. The aim of this study was to determine whether short-term improvement in submaximal exercise capacity induced by optimized therapy with ACE inhibitors in combination with beta blockers is associated with restoration of endothelial function in CHF patients. METHODS: Thirty-three patients with CHF were evaluated: six-minute walk test, NYHA class, brain natriuretic peptide (BNP), big Endothelin-1 (bigET-1) and flow-mediated vasodilation (FMD) of the brachial artery were assessed at baseline and after a 3-month period of optimized neurohormonal therapy. Two groups were formed retrospectively based on the changes in submaximal exercise capacity (responders and non-responders). RESULTS: Optimization of neurohormonal therapy was comparable between groups. Responders (n=17) revealed a significant increase in walking distance (304+/-109 to 441+/-75 m; p<0.01), which was paralleled by a decrease in NYHA class (2.7+/-0.6 to 2.0+/-0.4; p<0.01), BNP (484+/-454 to 243+/-197 pg/ml; p<0.01), and bigET-1 (2.0+/-0.9 vs. 1.5+/-0.6 fmol/ml; p=0.04). By contrast, the latter variables did not change in non-responders. Improvement in functional capacity in responders was associated with an increase in FMD (8.2+/-3.9% to 11.0+/-5.6%; p<0.05). Increments in FMD were directly correlated with increases in walking distance (r=0.34; p<0.05). CONCLUSION: Short-term improvement of submaximal exercise capacity in CHF patients following optimized therapy with ACE inhibitors and beta blockers is associated with restoration of endothelial function in conduit arteries. |
| | |
Authors:
|
Gerhard Poelzl; Matthias Frick; Benedikt Lackner; Heike Huegel; Hannes F Alber; Johannes Mair; Manfred Herold; Severin P Schwarzacher; Otmar Pachinger; Franz Weidinger |
Related Documents
:
|
7572657 - Lung-heart interaction as a substrate for the improvement in exercise capacity after bo... 15802367 - Impact of aging on muscle blood flow in chronic heart failure. 12634897 - Chemosensitivity in chronic heart failure. 17702647 - Excessive ventilation during early phase of exercise: a new predictor of poor long-term... 21225277 - Physiological fitness and health adaptations from purposeful training using off-road ve... 2459537 - Electrophysiologic effects of a novel ca antagonist, sa2572, in isolated rabbit and gui... |
Publication Detail:
|
Type: Comparative Study; Journal Article |
Journal Detail:
|
Title: International journal of cardiology Volume: 108 ISSN: 0167-5273 ISO Abbreviation: Int. J. Cardiol. Publication Date: 2006 Mar |
Date Detail:
|
Created Date: 2006-03-06 Completed Date: 2006-08-10 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8200291 Medline TA: Int J Cardiol Country: Ireland |
Other Details:
|
Languages: eng Pagination: 48-54 Citation Subset: IM |
Affiliation:
|
Clinical Division of Cardiology, Innsbruck Medical University, Anichstrasse 35, A-6020 Innsbruck, Austria. Gerhard.Poelzl@uklibk.ac.at |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenergic beta-Antagonists
/
therapeutic use* Adult Aged Angiotensin-Converting Enzyme Inhibitors / therapeutic use* Drug Therapy, Combination Endothelium, Vascular / drug effects*, physiopathology Exercise Tolerance / drug effects* Female Heart Failure / drug therapy*, physiopathology* Heart Rate / drug effects Humans Male Middle Aged Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic beta-Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Urotensin-II levels in acute coronary syndromes.
Next Document: CRP, interleukin-6, secretory phospholipase A2 group IIA, and intercellular adhesion molecule-1 duri...